2. Apoptosis Cell Cycle/DNA Damage MAPK/ERK Pathway Immunology/Inflammation
  3. Apoptosis DNA Alkylator/Crosslinker DNA/RNA Synthesis p38 MAPK JNK AP-1
  4. Nimustine

Nimustine is an alkylating agent, which induces DNA double-strand breaks (DSBs) and inter-strand crosslinks (ICLs), thereby activating the DNA damage response (DDR) signaling pathway. Nimustine activates p38 MAPK/JNK signaling pathway, and exhibits antitumor activity.

At equivalent molar concentrations, both the salt and free forms of a compound exhibit comparable biological activity. Nevertheless, the salt form (Nimustine hydrochloride) usually boasts enhanced water solubility and stability.

For research use only. We do not sell to patients.

Nimustine Chemical Structure

Nimustine Chemical Structure

CAS No. : 42471-28-3

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Nimustine:

Nimustine Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Nimustine

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK p38α p38β MAPK13 p38δ p38γ

View All JNK Isoform Specific Products:

View All Isoforms
JNK1 JNK2 JNK3 JNK

View All AP-1 Isoform Specific Products:

View All Isoforms
c-Fos c-Jun

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Nimustine is an alkylating agent, which induces DNA double-strand breaks (DSBs) and inter-strand crosslinks (ICLs), thereby activating the DNA damage response (DDR) signaling pathway. Nimustine activates p38 MAPK/JNK signaling pathway, and exhibits antitumor activity[1][2].

Cellular Effect
Cell Line Type Value Description References
SF-126 IC50
310 μM
Compound: ACNU
Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay in presence of O6-BG
Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay in presence of O6-BG
[PMID: 27041398]
SF-126 IC50
320 μM
Compound: ACNU
Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay
Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay
[PMID: 27041398]
SF-126 IC50
360 μM
Compound: ACNU
Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability pretreated with O6-BG for 2 hrs followed by addition of compound measured after 24 hrs by CCK8 assay
Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability pretreated with O6-BG for 2 hrs followed by addition of compound measured after 24 hrs by CCK8 assay
[PMID: 28197307]
SF-126 IC50
450 μM
Compound: ACNU
Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
[PMID: 28197307]
U-87MG ATCC IC50
0.84 μM
Compound: Nimustine
Cytotoxicity against human U87MG cells after 72 hrs by MTT assay
Cytotoxicity against human U87MG cells after 72 hrs by MTT assay
[PMID: 20184290]
In Vitro

Nimustine (50 μM, 72 h) activates caspase and AP-1, upregulates the expression of bim, promotes the phosphorylation of c-Jun, and induces apoptosis in cell LN-229[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Nimustine Related Antibodies

Apoptosis Analysis[1]

Cell Line: LN-229 cell line
Concentration: 50 μM
Incubation Time: 72-120 hours
Result: Time-dependently induced apoptosis.

Western Blot Analysis[1]

Cell Line: LN-229
Concentration: 50 μM
Incubation Time: 24-120 hours
Result: Increased the expressions of cleaved of bim and caspase-3/8/9.
In Vivo

Nimustine (15-30 mg/kg, iv, every two weeks for 2 doses, or once weekly for 4 doses) inhibits the tumor growth when combined with radiotherapy, exhibits toxicity in mice[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female C3H/HeN mice with solid FM3A tumors[2]
Dosage: 15 and 30 mg/kg
Administration: iv, every two weeks for 2 doses (30 mg/kg), or once weekly for 4 doses (15 mg/kg)
Result: Inhibited tumor growth. Caused weight loss and white blood cell (WBC) depression.
Clinical Trial
Molecular Weight

272.69

Formula

C9H13ClN6O2
CAS No.
SMILES

O=C(NCC1=CN=C(C)N=C1N)N(CCCl)N=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Nimustine Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Nimustine42471-28-3ApoptosisDNA Alkylator/CrosslinkerDNA/RNA Synthesisp38 MAPKJNKAP-1c-Jun N-terminal kinaseActivator Protein 1nitrosourea alkylatingapoptosisDNA damageMAPKanti-cancerLN-229gliomamiceFM3AInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Nimustine
Cat. No.:
HY-13703
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.